key: cord-0944974-sp3tixzc
authors: Rastogi, Ashu; Dogra, Himika; Jude, Edward B.
title: COVID-19 and peripheral arterial complications in people with diabetes and hypertension: A systematic review
date: 2021-07-09
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.102204
sha: 49ef75bddc05a38a0204585a0dfcee2b7a45fd3f
doc_id: 944974
cord_uid: sp3tixzc

AIMS: Identify the prevalence, risk factors and outcomes of lower extremity ischemic complications. METHODS: A systematic review was conducted by searching PubMed and SCOPUS databases for SARS-CoV-2, COVID-19 and peripheral arterial complications. RESULTS: Overall 476 articles were retrieved and 31 articles describing 133 patients were included. The mean age was 65.4 years. Pain and gangrene were the most common presentation. Hypertension (51.3%), diabetes (31.9%) and hypercholesterolemia (17.6%) were associated co-morbidities. Overall, 30.1% of patients died and amputation was required in 11.8% patients. CONCLUSIONS: COVID-19 patients with diabetes or hypertension are susceptible for lower limb complications and require therapeutic anti-coagulation.

The global pandemic of COVID-19 has stirred the scientific community not only because of the scale of infection affecting millions of individuals but also because of the varied presentations involving multiple organ systems. Though, COVID-19 characteristically involves the respiratory system causing acute respiratory distress syndrome (ARDS) even more distinctive is the complications of COVID-19 pertaining to the vascular system. COVID-19 is associated with cytokine storm that precipitates disseminated intravascular coagulation and thrombotic microangiopathy involving the medium and small size vessels. 1 Multiple thrombotic complications and presentations have been ascribed to COVID-19 mainly acute coronary syndrome, pulmonary thromboembolism, stroke, mesenteric ischemia, renal artery thrombosis and peripheral arterial disease (PAD). 2 Involvement of the peripheral vasculature is relatively uncommon but there has been a surge in reported cases of peripheral gangrene after COVID-19 infection. 2, 3 The cutaneous changes in COVID-19 secondary to arterial and venous thrombotic events manifest as gangrene of the extremities. The risk factors for peripheral gangrene in COVID-19 may be directly related to SARS-CoV-2 infection or secondary to cytokine storm, disseminated intravascular coagulation, hypercoagulability, thrombotic microangiopathy, use of inotropes in critically ill patients, cold antigen induced auto-immune phenomenon and complement activation or worsening of pre-existing diabetic peripheral vascular disease. 4 Peripheral gangrene in COVID-19 is more likely in patients with prior endothelial dysfunction secondary to hypertension or diabetes. 4 Patients with diabetes and foot complications are known to have poor survival and limb outcomes in the presence of co-existing peripheral arterial disease. 5 Studies have shown that patients with acute arterial thromboembolic lower limb complications due to COVID-19 are likely to have higher mortality (around 50%) compared to compared to similar patients without COVID-19. 6 Therefore, we performed a systematic review of the reported cases of peripheral gangrene in COVID-19 patients, co-existing comorbidities, specific treatment given, and outcomes of limb amputations or death.

We conducted a literature search in the electronic database of PubMed central and SCOPUS using MeSH terms "COVID-19"; SARS-CoV-2"AND "gangrene", "peripheral gangrene", "peripheral arterial disease". The words were used interchangeably for articles published in J o u r n a l P r e -p r o o f any language from Jan 2020 until 5 th June 2021. Two authors conducted an independent search for case reports, case series, intervention studies, original articles reporting peripheral gangrene as outcome in COVID-19 patients. Papers that included patients who became COVID-19 positive after the occurrence of peripheral ischemia were excluded from the analysis. All articles retrieved were collated, duplicates were removed and final list prepared.

In addition, reference list of the included articles were checked for additional cases. The demographic characteristics of patient population, symptom onset and duration, risk factors for peripheral arterial disease other than COVID-19 like the presence of diabetes, hypertension, hyperlipidaemia, coronary artery disease, and smoking status were noted. The duration of hospital stays, treatment offered for peripheral gangrene and outcomes in the form of limb amputation, mortality and reasons for mortality were noted.

Overall, 474 articles that described ischemic complications in COVID-19 patients were retrieved from PUBMED and SCOPUS. After removing duplicates, the title and abstract of 424 publications were studied. We further excluded publications that were unrelated to peripheral gangrene but focused on gangrene of other organs example. intestine, Fournier gangrene etc. Of the selected publications, 76 were review articles, commentaries or editorial and were excluded (Fig 1) . Finally, 31 articles describing 133 patients with peripheral gangrene in COVID-19 were included for analysis as shown in table 1. 7-37 The mean age of the subjects was 65.4 years with 81 males and 35 females (gender was not mentioned for 17 subjects). Mean duration of symptoms before hospital presentation was 7.4 days. Pain, paraesthesia, and gangrene of the affected extremity were the most common symptoms in addition to the COVID-19 related symptoms of fever, cough and respiratory complaints.

Other presentations related to peripheral extremities included swelling of leg, acrocyanosis, limb weakness, asthenia and ischemic ulcer. Majority of the articles did not mention the time from SARS-CoV-2 positivity to the onset of gangrene.

Details of pre-existing co-morbidities were available for 119 patients; hypertension was the most common associated co-morbidity present in 61 patients (51.3%), followed by diabetes in 38 (31.9%), hypercholesterolemia in 21 (17.6%), prior CAD in 19 (16.0%), COPD in 6 (5.0%), chronic kidney disease in 4 (3.4%), atrial fibrillation and prior stroke in 2 subjects each and hypothyroidism (0.84%) in one patient ( Figure 2 ). Anticoagulants were added to the COVID specific treatment for peripheral ischemia in 78.9% (n=105) of patients. Heparin was J o u r n a l P r e -p r o o f the most prescribed anti-coagulant (n=98), followed by dual anticoagulants (apixaban along with heparin) in 5 patients, warfarin only and apixaban only in one patient each. Overall, 30 .1% of patients (n=40) died during the hospital stay. COVID related ARDS and multiorgan failure (n=26, 65%) were the most common cause of death followed by acute coronary event (n=9, 22.5%) followed by invasive aspergillosis, pulmonary thromboembolism, stroke, terminal ileal perforation and intestinal bleeding in one patient each. All deaths were ascribed to severe COVID-19 illness. Amputation of the affected digit/limb was required in 11 of the 93 surviving of participants (11.8%).

We analyzed the prevalence, presentation and outcomes of peripheral vascular complications in people with COVID-19. Although millions of people are afflicted with COVID-19 globally, peripheral extremity complications are uncommon. Lower limb pain and gangrene are the most frequent presentations amongst those with peripheral arterial complications.

More than two-third of patients had risk factor for peripheral arterial disease including hypertension and diabetes. Almost one-third of the patients died and one in ten required limb amputations during the illness suggesting a poor prognosis.

COVID-19 is associated with a prothrombotic state and various thrombotic events predominantly involving the pulmonary and coronary vasculature in critically ill patients. 38, 39 The thrombotic events in COVID-19 may manifest as pulmonary thromboembolism and acute coronary events. The incidence of clinically manifest thrombotic events is much higher in SARS-CoV-2 infection as compared to other respiratory infections such as acute influenza or other viral infections. 40 However, autopsy studies have shown that alveolar microthrombi are nine times more common in COVID-19 patients. 41 The risk of arterial thrombotic events in COVID-19 correlates with the severity of the illness as most of the events are described in critically ill patients. The risk of thrombotic events prevails in COVID-19 patients despite thrombo-prophylaxis with heparin or low molecular weight heparin that is routinely administered to all admitted patients. 39 A good correlation has been found between systemic markers of inflammation like D-dimer, fibrinogen levels and risk of thrombosis in COVID-

pandemic and no correlation between D-dimer or fibrinogen and thromboembolic events.. 39 The coronary, pulmonary and venous thromboembolism are found to be more J o u r n a l P r e -p r o o f common than arterial thrombosis in COVID-19 which is testimony to very few cases of peripheral arterial manifestations in the literature. Peripheral arterial disease may manifest as acute lower limb pain, paraesthesias, livido reticularis, gangrene, or asymptomatic chilblain like lesions. We found that pain in the affected extremity and gangrene were the most common presenting features of peripheral arterial involvement in COVID-19 patients.

Thromboembolic risk in COVID-19 seems to be a systemic phenomenon secondary to disseminated intravascular coagulation as highlighted by markedly increased levels of inflammatory cytokineslike Il-6 and TNF-a. Also, there is a consistently increased level of fibrinogen, D-dimer, factor VIII, von Willebrand factor (vWF), and decreased antithrombin leading to a prothrombotic milieu in COVID-19. It is known that immobilized patients with critical illness are at heightened risk of thromboembolism, and COVID-9 further heightens the risk owing to a unique hypercoagulable mileu through a profound pro-inflammatory state. 43 It is proposed that viral entry into pneumocytes incites an inflammatory response that sets off a cascade of thrombosis initially localised to pulmonary vasculature and subsequent systemic response. COVID-19 is associated with endothelial injury as SARS-CoV-2 docking sites are the ACE2 receptor present on endothelial cells. It is known that SARS-CoV2 docks through its spike protein on to angiotensin-converting enzyme (ACE-2) present on the cell membrane and enters the cells. ACE-2 degrades angiotensin -II (Ang-II) and depletion of ACE-2 after binding of SARS-CoV2 to ACE-2 is associated with excess Ang-II. Ang-II binds to the Angiotensin receptor -1 and exacerbates the hypercoagulable state by increasing cytokine levels and induction of plasminogen activator inhibitor 1 (PAI-1) expression on endothelial cells. People with hypertension, diabetes and prior cardiovascular disease have reduced expression of ACE-2 that additionally contributes to high Ang-II levels in COVID- 19 . In addition, it has been proposed that heightened activation of monocytes and complement system confirmed by histopathological demonstration of pauci-inflammatory vasculitis with complement deposits in the affected vessel may also contribute to thrombotic microangiopathy 41 and peripheral gangrene in COVID-19.

We found that almost two-thirds of patients with reported peripheral arterial complications in COVID-19 had background hypertension, diabetes or dyslipidaemia. The risk of thrombotic peripheral arterial complications is increased manifold in patients with pre-existing endothelial dysfunction like hypertension and diabetes. 44 Diabetes (odds ratio of 2.72) and smoking(odds ratio of 1.88) are considered as the strongest risk factor for PAD. 45 It is known that diabetes being a pro-inflammatory state contributes to endothelial dysfunction, abnormal J o u r n a l P r e -p r o o f vascular smooth muscle cell (VSMC) migration into the intima layer of vessels, decreased endothelial nitric oxide synthase (eNOS) activity and platelet dysfunction that adds to hypercoagulability of COVID-19. 46 Almost one-fifth to one-third of people with diabetes have PAD that is related to the duration and severity of diabetes. 47 People with uncontrolled diabetes are more susceptible to severe COVID-19, requiring hospitalisation, thus increased likelihood of detection of peripheral arterial complications. We noticed that 10% of the subjects required limb amputation over a short duration of hospital stay and almost one fourth of the patients with COVID-19 identified in the present systematic review died due to acute coronary events that may be or not related to COVID-19. This emphasises the need for heightened screening for thrombotic complications amongst hospitalised patients with diabetes and COVID-19.

We found that almost all the patients were on therapeutic anticoagulation in the form of subcutaneous heparin (most frequent). Considering increased thrombotic risk in COVID-19, prophylactic or therapeutic anticoagulation is routinely prescribed in clinical practice.

Though, the doses and duration of anticoagulation were inadequately described amongst the reported cases suggesting lack of consensus. Similarly, there is controversy regarding the prophylactic or therapeutic use of anticoagulation especially for people with co-morbidities like diabetes. The risk of thrombotic complications persists despite appropriate prophylactic anticoagulation with increased thrombotic events especially in people with diabetes, though less frequent in those receiving therapeutic doses of anticoagulants. 48 On the other hand, there is a risk of fatal bleeding episodes on higher or therapeutic anticoagulation which require careful evaluation. However, a recent study found reduced rate of thrombotic complications without bleeding risk with therapeutic anticoagulation of LMWH (dose (100 IU/kg/12 h SC) or (UFH (500 IU/kg/24 h). 49 Also, a systematic review found a slightly reduced mortality in patients of COVID-19 receiving therapeutic anticoagulation. 50 Thus, people with heightened risk of thrombotic complications like diabetes may be offered therapeutic anticoagulation immediately on hospitalisation with severe COVID-19 (table 2) .

In conclusion, COVID-19 is a unique thrombo-inflammatory condition and patients with background diabetes or hypertension are more susceptible for lower limb complications due to peripheral arterial disease presenting as gangrene. The outcomes of COVID-19 with peripheral arterial complications are poor in terms of limb preservation and mortality. Considering the heightened risk of peripheral thrombotic complications in COVID-J o u r n a l P r e -p r o o f 19, therapeutic anticoagulation must be considered. Future studies are urgently needed to assess such treatments to reduce amputation and mortality. CHINA  n=7  71  F  -----11  --Y  -5 DEATH 

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Clinical Characteristics of Coronavirus Disease 2019 in China

COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Long term outcomes after incident diabetic foot ulcer: Multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study

Safety of transfer, type of procedure, and factors predictive of limb salvage in a modern series of acute limb ischemia

Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. ZhonghuaXue Ye Xue Za Zhi

Severe acute dried gangrene in COVID-19 infection: a case report

Characteristics, Laboratory Findings and Outcomes in J o u r n a l P r e

Acro-Ischemia in COVID-19 Patients. Vasc Health Risk Manag

Acral ischaemia with multiple microthromboses and imminent gangrene in a 73-year

COVID-19-associated leukocytoclastic vasculitis leading to gangrene and amputation. ID Cases

A 61-Year-Old Man with SARS-CoV-2 Infection and venous thrombosis presenting with painful swelling and gangrene of the lower limb consistent with phlegmasia cerulea dolens

Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic. Cureus

Axillary artery thrombosis resulting in upper limb amputation as a COVID-19 sequela

Unilateral deep vein thrombosis with gangrene involving the ascending aorta with sepsis and pulmonary thromboembolisma pertinent cutaneous marker of severity of COVID-19

Acral Gangrene: ugly Cousin Of "COVID Toes" In Multi-System Inflammatory Syndrome In Children Associated With SARS-COV-2?

A 47-Year-Old Hispanic Man Who Developed Cutaneous Vasculitic Lesions and Gangrene of the Toes Following Admission to Hospital with COVID-19 Pneumonia

A Case of Covid-19 Patient with Acute Limb Ischemia and Heparin Resistance

Phlegmasia cerulea dolens associated with acute coronavirus disease 2019 pneumonia despite anticoagulation. J Vasc Surg Cases Innov Tech

Covid-19 diagnosis in a patient with critical limb ischemia: Complications and clinical outcomes

COVID-19 With limb ischemic necrosis

An increased severity of peripheral arterial disease in the COVID-19 era

Endotheliitis in Coronavirus Disease 2019-Positive Patients After Extremity Amputation for Acute Thrombotic Events

Acro-ischaemia in hospitalized COVID-19 patients

Single-Center Vascular Hub Experience after 7 weeks of COVID-19 Pandemic in Lombardy

Acute Arterial Thromboembolism in Patients with COVID-19 in the New York City Area

Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19

Acute Limb Ischemia in Minimally Symptomatic SARS-CoV-2 Infection

Arterial Thrombotic Sequalae After Covid-19: Mind the Gap

COVID-19 Infection and Arterial Thrombosis: Report of Three Cases

Digital Ischemia in COVID-19 Patients: Case Report

Femoral Arterial Thrombosis in a Young Adult after Nonsevere COVID-19

Peripheral ischemic limb necrosis (Acro-ischemia) associated with severe COVID-19 patients (COVID-19 limbs): A report of three cases

Acute COVID-19 induced fulminant systemic vascular thrombosis: A novel entity

Successful Catheter-Directed Thrombolysis for Acute Lower Limb Ischemia Secondary to COVID-19 Infection

Systemic Thrombolysis as Initial Treatment of COVID-19 Associated Acute Aortoiliac and Lower Extremity Arterial Thrombosis

A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Thromboprophylaxis strategies to improve the prognosis of COVID-19

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Endothelial cell infection and endotheliitis in COVID-19

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis

Is diabetes a hypercoagulable state? A critical appraisal

Peripheral arterial disease in patients with diabetes

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review

 al 7   63  F  -----13  --(n=6)   -2 IMPROVED  59  M  Y  Y  ---11  ---49 M Shubhra, et al 15 Spain  n=3  -------17  Y  IMPROVED  -------24  Y  IMPROVED  -------28  Y  IMPROVED  19 Mascia Italy  n=2  53  M  -----7  Y  DEATH n=1  IMPROVED n=1  37  M  -----Y   22 Maureree, et al 28Borrelli, et al 29Kathryn, et al 31